A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
Status:
No longer available
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in
women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3
months. The anticipated time on study treatment is 3-12 months, and the target sample size is
100 individuals.